Hims & Hers to Launch Affordable Weight Loss Program in Canada with Generic Semaglutide
Krissy Vann | Host, All Things Fitness and Wellness
Hims & Hers Health has announced plans to expand into the Canadian market with a lower-cost, clinically supported weight loss program. The rollout is set to coincide with the anticipated global debut of generic semaglutide, a drug widely used in the treatment of obesity.
The move follows Hims & Hers’ recent acquisition of ZAVA, a digital health platform operating across Europe. The company said the expansion is part of a broader strategy to improve access to healthcare in markets with high demand but limited affordability.
According to Statistics Canada, nearly two-thirds of adults in the country are overweight or living with obesity. While drugs like semaglutide have shown clinical effectiveness, costs often exceed C$200 per month in Canada when purchased without additional clinical support. Generic versions are expected to enter the market at a lower price point, with further reductions anticipated as supply scales.
“Canada is a major opportunity to show what affordable, high-quality weight loss care can look like,” said Andrew Dudum, co-founder and CEO of Hims & Hers. “As generic semaglutide becomes available for the first time globally, we’re focused on making it truly accessible, by combining affordability with trusted, personalized care at scale.”
Hims & Hers plans to deliver the program through its digital platform, offering 24/7 access to licensed providers and care plans tailored to individual needs. The company emphasized its intent to integrate both medication and ongoing clinical support as part of its approach.
“Despite North America being the largest GLP-1 market, many still lack crucial access,” said David Meinertz, General Manager International at Hims & Hers. “Making affordable, holistic obesity treatment accessible has the potential to help strengthen the local healthcare system and unlock the potential for millions of Canadians to live healthier, more fulfilling lives.”
The planned entry into Canada marks a continued effort by Hims & Hers to grow its digital health footprint globally. With ZAVA now under its umbrella, the company is seeking to expand across markets where its hybrid model of telehealth, medication access, and ongoing support could address care gaps.
